BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 14702244)

  • 1. Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative.
    Marder SR; Fenton W; Youens K
    Am J Psychiatry; 2004 Jan; 161(1):25. PubMed ID: 14702244
    [No Abstract]   [Full Text] [Related]  

  • 2. The MATRICS initiative: developing a consensus cognitive battery for clinical trials.
    Green MF; Nuechterlein KH
    Schizophr Res; 2004 Dec; 72(1):1-3. PubMed ID: 15531401
    [No Abstract]   [Full Text] [Related]  

  • 3. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.
    Marder SR; Fenton W
    Schizophr Res; 2004 Dec; 72(1):5-9. PubMed ID: 15531402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
    Sharma T
    Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
    [No Abstract]   [Full Text] [Related]  

  • 5. Building a neurocognitive profile of thought disorder in schizophrenia using a standardized test battery.
    Tan EJ; Rossell SL
    Schizophr Res; 2014 Jan; 152(1):242-5. PubMed ID: 24291545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerobic exercise for cognitive deficits in schizophrenia - The impact of frequency, duration, and fidelity with target training intensity.
    Kimhy D; Lauriola V; Bartels MN; Armstrong HF; Vakhrusheva J; Ballon JS; Sloan RP
    Schizophr Res; 2016 Apr; 172(1-3):213-5. PubMed ID: 26852401
    [No Abstract]   [Full Text] [Related]  

  • 7. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
    Purdon SE
    J Psychiatry Neurosci; 2000 Mar; 25(2):108-16. PubMed ID: 10740984
    [No Abstract]   [Full Text] [Related]  

  • 8. Cognitive training for divergent thinking in schizophrenia: a pilot study.
    Nemoto T; Yamazawa R; Kobayashi H; Fujita N; Chino B; Fujii C; Kashima H; Rassovsky Y; Green MF; Mizuno M
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1533-6. PubMed ID: 19733608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions.
    Green MF
    Am J Psychiatry; 2007 Jul; 164(7):992-4. PubMed ID: 17606645
    [No Abstract]   [Full Text] [Related]  

  • 10. [Measuring the cognitive deficit associated with schizophrenia: presentation of the MATRICS neuropsychological test battery].
    Sarolta K; Pál C; István B
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):143-50. PubMed ID: 18399033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
    Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 13. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
    Cohen JD; Insel TR
    Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
    [No Abstract]   [Full Text] [Related]  

  • 14. Another view of therapy for cognition in schizophrenia.
    Carpenter WT; Gold JM
    Biol Psychiatry; 2002 Jun; 51(12):969-71. PubMed ID: 12062880
    [No Abstract]   [Full Text] [Related]  

  • 15. The MATRICS consensus cognitive battery: what we know 6 years later.
    Green MF; Harris JG; Nuechterlein KH
    Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
    [No Abstract]   [Full Text] [Related]  

  • 16. Researchers focus on recovery in schizophrenia.
    Friedrich MJ
    JAMA; 2014 Jul; 312(1):16-8. PubMed ID: 24942273
    [No Abstract]   [Full Text] [Related]  

  • 17. [Typical and atypical antipsychotics: Is there a difference in their influence on neurocognition?].
    Faber G; van Gool AR; Smid HG; Wiersma D; van den Bosch RJ
    Tijdschr Psychiatr; 2011; 53(2):107-17. PubMed ID: 21319067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia.
    Pietrzak RH; Olver J; Norman T; Piskulic D; Maruff P; Snyder PJ
    J Clin Exp Neuropsychol; 2009 Oct; 31(7):848-59. PubMed ID: 19142774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cognition disorders and psychotic states].
    Rouillon F
    Encephale; 2002; 28 Spec No 2 Pt 2():S7-10. PubMed ID: 12587347
    [No Abstract]   [Full Text] [Related]  

  • 20. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
    Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.